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Hepcidin, a phase II reactant secreted by hepatocytes, regulates cellular iron levels by increasing internalization of ferroportin-a
transmembrane protein facilitating egress of cellular iron. Chronic low-grade inflammatory states, such as obesity, have been shown
to increase oxidative stress and enhance hepcidin secretion from hepatocytes and macrophages. Heme-heme oxygenase (HO) is a
stress response system which reduces oxidative stress. We investigated the effects of HO-1 induction on hepatic hepcidin levels and
on iron homeostasis in hepatic tissues from lean and obese mice. Obese mice exhibited hyperglycemia (𝑝 < 0.05); increased levels
of proinflammatory cytokines (MCP-1, IL-6,𝑝 < 0.05); oxidative stress (𝑝 < 0.05); and increased hepatic hepcidin levels (𝑝 < 0.05).
Enhancement of hepcidin was reflected in the reduced expression of ferroportin in obese mice (𝑝 < 0.05). However, this effect is
accompanied by a significant decline in ferritin expression. Additionally, there are reduced insulin receptor phosphorylation and
attenuation of metabolic regulators pAMPK, pAKT, and pLKB1. Cobalt protoporphyrin- (CoPP-) induced HO-1 upregulation in
obese mice reversed these alterations (𝑝 < 0.05), while attenuating hepatic hepcidin levels. These effects of CoPP were prevented
in obese mice concurrently exposed to an inhibitor of HO (SnMP) (𝑝 < 0.05). Our results highlight a modulatory effect of HO on
iron homeostasis mediated through the suppression of hepatic hepcidin.
1. Introduction
Oxidative stress contributes to the development, and/or
progression, of numerous acute and chronic pathological
states. Contextually, the role of reactive oxygen species
(ROS) in complex multifactorial disorders, such as obesity,
fatty liver, and metabolic syndrome has received widespread
attention, and obesity is now characterized as a chronic low-
grade inflammatory state. In this regard, intracellular free
iron is cytotoxic, drives the Fenton reaction, and exacer-
bates oxidative stress [1–4]. Intracellular iron homeostasis
is regulated by a complex crosstalk between the peptide-
hepcidin, a near ubiquitous transmembrane protein ferro-
portin, and an intracellular iron binding protein, ferritin.
Hepcidin downregulates ferroportin and reduces egress of
excess intracellular irons that can then bind to IRP-1 and
induce iron responsive genes, including ferritin [5–7]. In the
face of an insufficient ferritin upregulation, free iron can exert
its prooxidant and cytotoxic effects. These molecular events
feed-forward on ROS and contribute to the escalation of
pathophysiological alterations in conditions, such as NAFLD
and obesity [1–3, 8, 9]. The crucial importance of ferritin
in the protection of the liver to oxidative insult is further
corroborated in ischemia reperfusion injury [10].
Upregulation of the cytoprotective enzyme system, heme
oxygenase (HO), is an essential process and has been shown
in the past to alleviate and prevent several pathological
conditions, including adipocyte dysfunction and obesity [8,
11–17]. Heme-HO system metabolizes heme to equimolar
concentrations of biliverdin (BV), carbon monoxide (CO),
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and iron. While biliverdin is a potent natural antioxidant,
alleviating lipid peroxidation, CO has vasodilatory and
antiapoptotic properties [4]. Pharmacogenetic induction of
the inducible HO isoform (HO-1) leads to attenuation of
adiposity along with restoration of insulin sensitivity and
abatement of chronic inflammation, cardiomyopathy [18],
and pathophysiological insults frequently associatedwith diet
induced obesity [2, 3, 8, 11, 19–22]. These effects of HO-1
induction have been associated with its stimulatory effects
on adiponectin secretion, with a subsequent activation of
pLKB1/pAMPK-dependent pathways [23].
Serum hepcidin and hepatic iron content are positively
correlated with obesity in human subjects [24], an obser-
vation corroborated in obese adolescents and children [25].
For the current study, we hypothesize that HO-1 induction
will restore hepatic redox balance, reduce hepcidin secretion,
and restore mitochondrial integrity. Observations were first
contrasted in experiments conducted in lean and obese mice
followed by characterization of a modulatory role of HO-
1 by conducting experiments in obese mice treated with
and without CoPP, in the absence or presence of an HO-
1 inhibitor, SnMP. Our results show that obese mice have
increased hepatic levels of hepcidin complemented by lower
expression of ferroportin and ferritin with increased levels
of NRF2 and gp91phox, an indication of oxidative stress.
CoPP-mediated HO-1 induction reverses these alterations in
obese mice along with a significant improvement in insulin
sensitivity, decreased hepcidin, and increased ferroportin
and mitochondrial Mfn-1/2 levels. The fact that these rescue
effects of CoPP in obese mice are prevented inmice cotreated
with SnMP corroborates the regulatory role of heme-HO
system in iron homeostasis.
2. Materials and Methods
2.1. Animal Treatment. All experiments were performed fol-
lowing an IACUC approved protocol in accordance with the
NIH Guide for the Care and Use of Laboratory Animals. Male
obese (ob) mice (B6v-Lep ob/J) were purchased from Harlan
(Chicago, IL) at the age of 7 weeks and used at the age of 8
weeks. Age- and sex-matched lean mice (B6.V, lean; Harlan)
were used as controls. Mice were fed a normal chow diet
and had free access to water. Body weights of the mice at the
beginning of the treatmentwere 23.7±2.5 g for lean and 35.7±
4.7 g for obese mice. Glucose levels were 129.2 ± 10.8mg/dl
and 209.7 ± 6.8mg/dl for lean and obese mice, respectively.
Glucose monitoring was performed using an automated
analyzer (Life scan, Milpitas, CA). Cobalt protoporphyrin
(CoPP), an inducer of HO-1, was given intraperitoneally
once a week (3mg/kg) for 6 weeks to obese mice. CoPP
plus stannous mesoporphyrin (SnMP), to inhibit HO activ-
ity, was administered intraperitoneally three times a week
(20mg/kg) for 6 weeks [26] to ascertain that any effects
of CoPP treatment were related to increased HO activity.
Metalloporphyrins were dissolved in 10mmol/l Tris base, and
the pH was adjusted to pH 7.8 with 0.1 N HCl. A Tris/HCl
solution free of Metalloporphyrins was used to inject control
animals. The animals were equally divided into four groups:
(1) lean, (2) obese (3) obese CoPP, and (4) obese CoPPSnMP.
Food intake did not change in the mice treated with the
various treatments. At the time of sacrifice, the body weight
of all mice was measured. After a 6-hour fast, mice were
anesthetized with sodium pentobarbital (65mg/kg, i.p.) and
blood was obtained from a tail vein for glucose measurement
using a glucometer. Blood samples were collected in K
3
EDTA
tubes at sacrifice and the plasma was separated. Samples were
flash frozen in liquid nitrogen and maintained at −80∘C until
needed.
2.2. Plasma Cytokines Measurements. TNF-alpha and IL-6
in plasma were determined using an ELISA assay (Pierce
Biotechnology, Inc., Woburn, MA) as previously described
[27].
2.3. Western Blot Analysis
2.3.1. Tissue Preparation for Western Blot. After 6 weeks of
treatments the mice were killed, and the liver was harvested,
drained of blood, and flash frozen in liquid nitrogen. Livers
were maintained at −80∘C until needed.
2.3.2. Fractionation of Microsomal and Nuclear Fractions.
Frozen pieces of liver were placed in a homogenizing buffer
consisting in mmol/l of 10 phosphate buffer, 250 sucrose, 1
EDTA, 0.1 PMSF, and 0.1% v/v Tergitol, pH 7.5. The nuclear
fractions were obtained using Nuclear Extraction Reagents
(Thermo Scientific, Rockford, IL, USA) according to the
manufacturer’s protocol. Homogenates were centrifuged at
27.000𝑔 for 10min at 4∘C to remove cell debris; then the
supernatant was isolated and protein levels were assayed
(Bradford method). After mixing samples with loading
buffer (Tris-Cl 50mM, SDS 10% w/v, glycerol 10% v/v, 2-
mercaptoethanol 10% v/v, and bromophenol blue 0.04%) at a
of ratio 4 : 1, they were boiled for 5min. In brief, 20 𝜇g protein
was loaded onto 8% or 12% SDS-polyacrylamide gels and
subjected to electrophoresis (90V, 100min). The separated
proteins were transferred onto 0.45 𝜇m PVDF membranes
(Millipore, Billerica, MA, USA) for 1 h (140mA). After trans-
fer, the blots were incubated with Blocking Buffer Solution
(Odyssey, LI-COR Biosciences, Lincoln, NE, USA) at room
temperature for 1 hour with constant shaking. Then, the
membranes were incubated with various antibodies against
specific proteins: HO-1, HO-2, and ferritin heavy chain
(Cell Signaling Technology, Boston, MA, USA), ferroportin-
1 (Santa Cruz Biotechnology, CA, USNFR-2 (Abcam), gp91
phox, UCP1, and UCP2 (Abcam), insulin receptor beta Cell
Signaling Technology), insulin receptor phosphorylated at
Tyr 1146 (Cell Signaling Technology) and at Tyr 1322 (Assay
Design, Ann Arbor, MI, USA), and AKT, pAKT, AMPK,
pAMPK, Mfn1, and Mfn 2 (Cell Signaling Technology)
at 4∘C overnight with constant shaking. The blots were
washed in TBS 1x and subsequently were incubated with
fluorophore-conjugated secondary antibodies (IRDye, LI-
COR Biosciences). Finally, the blots were developed using an
Infrared Imaging System (Odyssey, LI-COR Biosciences).
2.4. RNA Extraction and Real-Time PCR. Total RNA was
extracted from mice liver using RNeasy Protect Mini kit
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Figure 1: Effect of HO-1 induction on body weight and plasma levels of inflammatory cytokines in lean and obese mice. (a) Effect of CoPP
and SnMP coadministration on body weight of obese mice after 6 weeks of treatment. The data are the weights in grams as mean ± SEM
(𝑝 < 0.05). (b) TNF-𝛼 plasma levels and (c) IL-6 plasma levels results are mean ± SEM 𝑛 = 3-4, ∗𝑝 < 0.05 versus lean; #𝑝 < 0.05 versus obese;
+𝑝 < 0.05 versus obese CoPP.
(QIAGEN, Maryland, USA) according to the manufacturer’s
instructions. Total RNA (1𝜇g) was transcribed into cDNA
using GeneAmp kit (Applied Biosystems, Branchburg, NJ,
USA) reverse transcription reagents. Total RNAwas analyzed
by a quantitative real-time polymerase chain reaction (qRT-
PCR). Real-time PCRwas performed using SYBRGreen PCR
Master Mix (Applied Biosystems) on a 7500HT Fast Real-
Time PCR System (Applied Biosystems). Specific primers
for mouse ferritin heavy chain and hepcidin were used. The
mouse ferritin heavy chain amplification primers were Fwd
5󸀠-XXX-3󸀠 and Rev 5󸀠-XXX-3󸀠, while the mouse hepcidin
amplification primers were Fwd 5󸀠-CCAGCCTGAGCA-
GCACCACC-3󸀠 and Rev 5󸀠-TTGAGGGGCTGCAGGGGT-
GT-3󸀠 (Integrated DNA Technologies). Each reaction was
performed in triplicate. The comparative threshold cycle
(Ct) method was used to calculate the fold amplification as
specified by themanufacturer. All experimental samples were
normalized using 18s as an internal control.
2.5. Statistical Analyses. Statistical significance between ex-
perimental groups was determined by ANOVA with Tukey-
Kramer post hoc analysis. The data are presented as means ±
SE and the null hypothesis was rejected at 𝑝 < 0.05, 𝑛 ≥ 3.
3. Results
3.1. Phenotype of Lean and Obese Mice, in the Absence or
Presence of CoPP. As shown in Figure 1(a), obese mice
weighed significantly (𝑝 < 0.05) more than lean mice. CoPP
treatment prevented (𝑝 < 0.05) weight gain in obese mice
and normalized body weight as compared with age-matched
lean controls. This effect of CoPP was offset (𝑝 < 0.05) in
obese mice concurrently treated with SnMP. Complementary
experiments examining markers of chronic inflammation
revealed significantly higher levels of TNF-𝛼 (𝑝 < 0.05) and
IL-6 in obesemice, as compared to age-matched lean controls
(Figures 1(b) and 1(c), resp.). Treatment of obese mice with
CoPP resulted in a significant (𝑝 < 0.05) decrease in these
proinflammatory cytokines; an effect that was prevented (𝑝 <
0.05) by SnMP treatment (Figures 1(b) and 1(c)).
Complementary experiments reveal elevated plasma glu-
cose level in obese mice, which is prevented in CoPP treated
mice.This reversal in plasma glucose is not seen in obesemice
concurrently exposed to SnMP (Figures 1(a), 1(b), and 1(c)).
3.2. Redox Balance in Hepatic Tissues of Lean and Obese Mice,
in the Absence or Presence of CoPP. The redox state of these
mice was assessed in hepatic tissue via expression analysis of
the oxidant enzyme, gp91phox, and by levels of antioxidant
response proteins, that is, glutathione s peroxidase (GST) and
Nrf2 (Figures 2(a), 2(b), and 2(c), resp.). Obese mice had
significantly higher levels of oxidative stress as characterized
by increased (𝑝 < 0.05) levels of gp91phox and the antiox-
idant proteins GST and Nrf2 (Figures 2(a)–2(c)). CoPP
treatment (𝑝 < 0.05) increased gp91phox, GST, and Nrf2
levels, which is indicative of a restoration of the redox balance
in obese mice (Figures 2(a)–2(c)).
In spite of increased nuclear Nrf2, a transcriptional
coregulator of HO-1, HO-1 levels was not enhanced in obese
mice; on the contrary, there was a significant (𝑝 < 0.05)
attenuation of HO-1 (Figure 2(d)). HO-1 expression was
enhanced (𝑝 < 0.05) in both CoPP and SnMP treated mice,
without any effect on hepatic HO-2 levels (Figure 2(e)).
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Figure 2: Effect of HO-1 induction on gp91phox, GST, and nuclear NRF2 protein levels in liver of lean and obese mice. Western blot and
densitometry analysis of (a) gp91phox, (b) GST, (c) nuclear NRF2, (d) HO-1, and (e) HO-2 protein levels. Results are mean ± SEM of the band
density normalized to actin. 𝑛 = 3-4, ∗𝑝 < 0.05 versus lean; #𝑝 < 0.05 versus obese; +𝑝 < 0.05 versus obese CoPP.
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Figure 3: Effect of HO-1 induction on hepcidin, ferroportin, and ferritin levels in liver of lean and obese mice. (a) Hepcidin mRNA levels,
(b) ferroportin protein levels, and ferritin mRNA and protein levels in (c) and (d), respectively. Results are mean ± SEM. 𝑛 = 3-4, ∗𝑝 < 0.05
versus lean; #𝑝 < 0.05 versus obese; +𝑝 < 0.05 versus obese CoPP.
3.3. Iron Homeostasis in Lean and Obese Mice, Treated with
andwithout CoPP. As shown in Figure 3(a), hepatic hepcidin
expression was significantly (𝑝 < 0.05) increased in obese
mice as compared to their lean counterparts.This phenotypic
alteration was reversed (𝑝 < 0.05) in mice undergoing treat-
ment with CoPP. Increased hepatic hepcidin affected cellular
ferroportin levels as expected, demonstrating a significant
decline in obese mice (Figure 3(b)). Reduced ferroportin
facilitates cellular iron overload, thus activating translation
of iron responsive genes, including ferritin. However, coun-
terintuitively, hepatic ferritin levels were significantly lower
in obese mice (𝑝 < 0.05) (Figures 3(c) and 3(d)). CoPP
treatment rescued (𝑝 < 0.05) hepatic ferroportin and
ferritin levels in obese mice. Cotreatment with SnMP, in
CoPP treated obese mice, prevented the protective effects
of CoPP on hepcidin, ferroportin, and ferritin expression,
corroborating the role of heme-HOsystem inmediating these
effects (Figures 3(a)–3(d)).
3.4. Effect of HO-1 Induction on Insulin Receptor in Liver
Microsomal Fraction. Western blot analyses of generic
insulin receptor beta showed a significant (𝑝 < 0.05) decrease
in obese mice as compared with their lean controls (Fig-
ure 4(a)). This decrease was blocked by the administration of
CoPP, while coadministration of CoPP and SnMP returned
their levels to the untreated obese expression (Figure 4(a)).
Similar results were observed in the expression of liver insulin
receptor phosphorylated at tyrosine 1466 and at tyrosine 1322
(Figures 4(b) and 4(c)).
3.5. Effect of CoPP Treatment on pAMPK/AMPK and pAKT/
AKT Ratio in Liver Microsomal Fraction. Downregulation
of insulin receptors and their phosphorylation was comple-
mented by reduced (𝑝 < 0.05) pAMPK/AMPK ratio in
obese mice (Figure 5(a)). This decrease was blocked by the
administration of CoPP, while the coadministration of CoPP
6 Journal of Nutrition and Metabolism
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Figure 4: Effect of CoPP and SnMP administration on insulin receptor-𝛽, insulin receptor phosphorylated at tyrosine 1146, and insulin
receptor phosphorylated at tyrosine 1322 protein levels in liver of lean and obese mice. (a) Total insulin receptor-𝛽 (IR-𝛽) protein levels,
IR-𝛽 phosphorylation at (b) tyrosine 1146, and (c) tyrosine 1322. Results are mean ± SEM of the bands density normalized to actin. 𝑛 = 3-4,
∗𝑝 < 0.05 versus lean; #𝑝 < 0.05 versus obese; +𝑝 < 0.05 versus obese CoPP.
and SnMP returned this ratio to the levels seen in untreated
obese mice (Figure 5(a)). A similar pattern was observed
in hepatic expression of pAKT and its upstream regulator,
that is, pLKB1 (Figures 5(b) and 5(c)). As obese mice had
suppressed (𝑝 < 0.05) levels of these metabolic regulators,
CoPP treatment abated this effect (Figures 5(b) and 5(c)).The
underlying role of HO-1 induction, via CoPP, in mediating
these effects was corroborated by loss (𝑝 < 0.05) of the
protective effects of CoPP in animals treated with the HO-1
inhibitor, SnMP (Figures 5(b) and 5(c)).
3.6. Effect of CoPP Treatment on Mitochondria Energy
Expenditure- and Fusion-Associated Proteins. Western blot
analyses of uncoupling proteins 1 and 2 showed a significant
(𝑝 < 0.05) increase in obese mice treated with CoPP as com-
pared with their obese controls (Figures 6(a) and 6(b)). This
increase was blocked by the concomitant administration of
SnMP (Figures 6(a) and 6(b)). Similar results were observed
in the expression ofmitochondrial fusion-associated proteins
mitofusins 1 and 2 (Figures 6(c) and 6(d), resp.).
4. Discussion
The first key finding presented in this study is the suppressive
effect of HO-1 induction on hepatic hepcidin levels in
a murine model of obesity. Hepcidin is secreted mostly
from hepatocytes and less from macrophages and plays a
central role in iron homeostasis [28]. An elevated hepcidin
Journal of Nutrition and Metabolism 7
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Figure 5: Effect of CoPP and SnMP administration on pAMPK/AMPK and pAKT/AKT protein levels in liver of lean and obese mice. (a)
Total and phosphorylated AMPK, and pAMPK/AMPK, (b) total and phosphorylated AKT, and pAKT/AKT, and (c) total and phosphorylated
LKB1, and pLKB1/LKB1. Results are mean ± SEM, 𝑛 = 3-4, ∗𝑝 < 0.05 versus lean; #𝑝 < 0.05 versus obese; +𝑝 < 0.05 versus obese CoPP.
level inhibits duodenal iron absorption and is implicated
as the central pathophysiological alteration in anemia of
chronic disease [6, 29]. Plasma hepcidin levels are increased
in chronic inflammatory states frequently associated with
oxidative stress, such as obesity, metabolic syndrome, and
atherosclerosis [6, 30–32]. It is noteworthy, however, that
some studies have also shown reduced hepcidin levels in
conditions of oxidative stress [33]. Regardless, higher cir-
culating levels of hepcidin can induce downregulation of
the iron transport protein ferroportin from cellular plasma
membranes throughout the body [7]. We show here that
obesemice have increased hepatic hepcidin expression with a
concomitant suppressive effect on ferroportin, the sole egress
portal for excess cellular iron. These pathological alterations,
together, have the potential to promote intracellular iron
accumulation. Excess free iron is not only cytotoxic but
also promotes oxidative stress via facilitating conversion of
hydrogen peroxide to the hydroxyl radical (OH∙), the Fenton
reaction.The hydroxyl radical is one of the most reactive free
radicals in biological systems and reacts near its diffusion
limit. It can cause membrane damage, DNA and RNA
fragmentation, and lipid peroxidation, while contributing to
redox imbalance [34].
In an iron-replete cell, excess iron is exported from the
cell via a transmembrane protein, ferroportin. In chronic
inflammatory states, such as obesity, hepcidin-induced cyto-
plasmic recycling and lysosomal degradation of ferroportin
trap excess iron in the cell [5–7]. This free iron forms a
[4Fe-4S] cluster with iron regulatory protein 1 (IRP1), thus
disengaging it from iron response elements (IRE) [35]. IRP1
controls the translation, and/or stability, of several mRNAs of
iron responsive genes by binding to iron responsive elements
within their untranslated regions. Ferritin has the capacity
to bind thousands of ferric ions, thus keeping them out
of solution. Intracellular iron overload, a consequence of
ferroportin downregulation, posttranscriptionally activates
8 Journal of Nutrition and Metabolism
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Figure 6: Effect of CoPP and SnMP administration on UCP-1 and UCP-2, and Mfn-1 and Mfn-2 protein levels in liver of lean and obese
mice. Representative blots and associated graphs depicting densitometric analysis relative to 𝛽-actin of (a) UCP-1, (b) UCP-2, (c) Mfn-1, and
(d) Mfn-2. Results are mean ± SEM, 𝑛 = 3-4, ∗𝑝 < 0.05 versus obese control; #𝑝 < 0.05 versus obese treated with CoPP.
ferritin expression by delivering it from the inhibitory effect
of IRP1 [36]. However, the prooxidant properties of iron
predispose the iron overloaded cell to redox imbalance.
This iron-induced oxidative stress can destabilize the cubane
[4Fe-4S] clusters [37].
Ferritin upregulation, in parallel to iron accumulation,
is central to the sustenance of iron homeostasis. Apart from
keeping iron out of solution in the cytosol, ferritin also has
antioxidant [38] and anti-inflammatory properties [39].
The second key finding presented in this study delineates
the facilitatory role of HO-1 in cellular ferritin levels. Rescue
of ferritin expression, in CoPP treated mice, highlights the
role of HO-1-mediated antioxidant effect in allowing ferritin
upregulation in face of a cellular iron overload. Antioxidant
properties of HO-1 have been largely ascribed to generation
of BV, which reduces oxidative stress via attenuation of lipid
peroxidation. BV-dependent restoration of redox homeosta-
sis could offset the inhibitory effect of ROS on IRP-[4Fe-4S]
complex, thus, allowing disengagement of IRP-1 from and
translation of the ferritin mRNA. Consequentially, this cir-
cuitous loop of iron-induced oxidative stress suppressing
ferritin, leading to increased free iron,which in turn enhances
ROS generation, is interrupted by HO-1 upregulation.
Another possibility for reduced ferritin expression could
be the inflammatory milieu of obesity. It is plausible that
inflammatory cytokines, by a yet unknown mechanism, may
be disrupting ferritin regulation. It could also be interplay
of an oxidative redox state and the inflammatory milieu. In
any case, HO-induced rescue of ferritin is quite remarkable
and could be linked to either the antioxidant or the anti-
inflammatory or an unrelated effect of HO. Although CoPP
may have affected other signaling pathways in cells, our
conclusions of HO-mediated ferritin rescue are strengthened
by the fact the HO-inhibitor is able to block ferritin rescue in
obesemice treatedwithCoPP.Another potential limitation of
these conclusions is the fact that we did not measure plasma
ferritin or transferrin levels. It is unlikely but possible that
cellular levels are different from those in the plasma.
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Enhanced ROS generation contributes to insulin resis-
tance and dysregulation of downstream metabolic targets,
that is, AMPK, LKB1, and AKT. P-AMPK is known to act in
the regulation of cell survival, protect against oxidative stress,
and, when activated, contribute to glucose transport, fatty
acid oxidation, and increased mitochondrial function. LKB1
is a serine-threonine kinase that directly phosphorylates
AMPK and improves glucose tolerance. Hepatic AMPK
activation facilitates [40] insulin-dependent inhibition of glu-
coneogenesis. Redox-dependent attenuation of LKB1 phos-
phorylation [41] prevented AMPK activation in obese mice.
Lack of AMPK activation increases hepatic glucose output
and contributes to hyperglycemia, while furthering insulin
resistance.
Our third key finding demonstrates that HO-1 induction,
in obese mice, lowers cellular redox and enhances AMPK
and AKT phosphorylation. These changes are accompa-
nied by an improved metabolic profile in these animals
exemplified by reduced body weight and lowering of blood
glucose levels. Also, HO-1/HO-2 are involved in regulation
of mitochondrial biogenesis, quality control, function, and
levels of cytochrome oxidase as well as apoptosis [4, 42–
45] and we have shown that HO-1 is present in the mito-
chondrial inner membrane and cortex [42]. We found that
CoPP-mediated induction of HO-1 in obese mice showed
improved mitochondrial energy expenditure and increased
fusion-associated parameters as compared to obese control
mice. Even though a HF diet itself did not reduce Mfn
and UCP levels in liver tissues, the CoPP-mediated increase
was effectively reduced in mice concomitantly treated with
the HO-inhibitor, SnMP, corroborating our recent report
showing that impaired HO-expression and activity decrease
mitochondrial function in adipose tissues of obese mice and
3T3-L1-derived adipocytes, contributing to increased mito-
chondrial derived superoxide formation [12, 46]. Mice defi-
cient in Mfn1, Mfn2, and OPA1 are all embryonic lethal [47]
and in humans, mutations in OPA1 are linked to hereditary
blindness, and Mfn2 mutations are known to cause Charcot-
Marie-Tooth disease [47–49]. In mice, a liver-specific knock-
out of Mfn2 is associated with impaired insulin signaling and
glucose metabolism [50]. Our results show that HO-1 induc-
tion increases mitochondrial energy metabolism and fusion-
associated processes are supported by a recent report inwhich
doxorubicin-induced oxidative stress increased mitochon-
drial fragmentation and Fis1 expression, an effect that was
prevented by HO-1 induction favoring expression of Mfn1
and Mfn2 [18, 45]. It should be noted, however, that antioxi-
dant and anti-inflammatory properties of the HOmay not be
observed under all conditions [51]. In contrast, humans with
deleted HO-1 suffer severe oxidative stress and organ failure
[13, 14, 52, 53]. These authors further showed that a defect in
iron recycling accounts for dysregulation of iron homeostasis
in human with heme oxygenase-1 deficiency [17].
This does not appear to translate to the presentation
of NAFLD in humans. Two-thirds of the US population
are overweight or obese [54]. 30% of the US population
has NAFLD. Serum ferritin is an independent predictor of
advanced fibrosis and even histologic severity in NAFLD [55,
56]. Iron metabolism appears to be altered in NAFLD. Most
food contains glucose and iron, resulting in hyperglycemia,
diabetes, and iron overload [57].This iron overload stimulates
hepcidin secretion. It is not clear whether the elevated
hepcidin secretion is from the inflammation of obesity or the
inflammatory effects of iron overload, or both. Only 20% of
these patients have elevated ferritin levels, which is associated
with advanced liver fibrosis [55].
It is clear that the results of our study show that iron
metabolism is altered in NAFLD. What is unclear is how
ferritin goes from having a protective role in a normal liver
to being the independent predictor of advanced fibrosis.
More work needs to be done to unravel the dilemma of iron
metabolism alterations in NAFLD.
Thus, our results show that chronic low-grade inflam-
mation and oxidative stress promote hepatic hepcidin secre-
tion which then attenuates cellular ferroportin levels. These
events could create an iron overload in the cell, whose
prooxidant properties exacerbate the metabolic imbalance
and interfere with upregulation of ferritin. HO-1 induction
attenuates hepatic hepcidin synthesis and restores redox
balance. Consequently, rescue of ferroportin and ferritin
expression counteract cellular iron overload and abate iron-
induced oxidative stress. The pathophysiological impact of
HO-1 induction includes improved mitochondrial energetics
and overall improvement of the mouse-metabolic profile.
Future studies in mouse-models of nonalcoholic fatty liver
and nonalcoholic steatohepatitis may provide additional evi-
dence to support the role of HO-induction in the treatment
of these metabolic disorders.
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